A peer reviewed platform from Russia's Skoltech (Skolkovo Institute of Science and Technology) screens antibiotic candidates against bacterial RNA synthesis, a step few marketed antibiotics touch. The pathogen is Pseudomonas aeruginosa.
Most antibiotics on the market attack one of a handful of bacterial processes, and resistance now follows every class that enters clinical use. A peer-reviewed platform from Skoltech opens a step the bacterial world has barely touched: RNA synthesis.
The system, described in the International Journal of Molecular Sciences and funded by a Russian Science Foundation grant, is a bacterial reporter assay that lights up when a candidate compound disrupts the machinery gram-negative pathogens use to read their genes.
The scope of the announcement is narrow by design. The team has built the early-stage screening step that gram-negative antibiotic discovery has been missing: an automated, quantitative readout aimed at the class whose outer membrane blocks most large-molecule antibiotics and which dominates the World Health Organization priority pathogen list.
Gram-negative bacteria include Pseudomonas aeruginosa, a leading cause of ventilator-associated and burn-wound infections that colonizes medical equipment surfaces and water systems. P. aeruginosa has accumulated resistance to successive antibiotic classes over the past half-century, according to a release on the work carried by Scoop, and contemporary hospital isolates now shrug off drugs that worked against earlier strains.
The existing antibiotic arsenal draws heavily from a small set of mechanisms: cell-wall synthesis, ribosomal protein synthesis, DNA replication, and a handful of metabolic pathways. Each has been hit hard enough that bacterial resistance is now widespread. RNA synthesis sits mostly outside that list. Few marketed compounds attack it, which means bacterial populations carry less pre-existing resistance pressure to draw on.
A reporter system is a routine molecular-biology assay that ties a visible signal, fluorescence or luminescence, to the activity of a specific cellular pathway. The Skoltech version is calibrated to gram-negative biology and uses P. aeruginosa as the workhorse organism, according to a GXP News carry of the team's release. Gram-negative bugs are harder to engineer with these assays than gram-positives such as Staphylococcus aureus, a common skin bacterium that turns dangerous when immunity drops. Most existing platforms came pre-built for that class.
The release adds a useful nuance: resistance to a single RNA-synthesis inhibitor does not doom the target class, since chemical modification of a scaffold can often restore potency. That gives outside chemistry groups a fresh mechanism to screen against.
Independent validation by groups outside the Skoltech collaboration is the next test. The reporting on the work currently runs through a university press release carried by Scoop and GXP News, and no external expert reaction to the screening results is included. Outside groups will need to run the platform against their own compound libraries to confirm the screen identifies what it claims to identify.
If that test holds, the contribution is a new door. Antibiotic discovery has spent decades screening the same exhausted targets. The Skoltech platform adds one more entry point, against a mechanism the bacterial world has had little reason to defend.